

RYSTIGGO (ROZANOLIXIZUMAB-NOLI) ORDER SET

P: 945.212.3707 **| F:** 866.790.3580

| | | | □н | ome Infusion | Alternate Site of Care |
|-------------------------|--|------------------------------------|-----------------------------|-----------------------|---|
| PATIENT | INFORMATION: | Fax completed form, | insurance informati | on, and clinical docu | umentation to 866.760.3580 |
| Patient Name | e: | | DOB: | Phor | ne: |
| | IS: □ New to Therapy | ☐ Continuing Thera | py Next Trea | atment Date: | |
| MEDICAL I | NFORMATION | | | | |
| Diagnosis: | ☐ Myasthenia Gra☐ Myasthenia Gra☐ Other: | vis w/acute exac | erbation (IC | D-10: G70.01) |) |
| gMG Classi | ification: 🗌 🛮 🗎 🗓 | I 🗆 IV | | | |
| Patient Wei | ght: lbs. (re | quired) Allergies: | | | |
| | | | | | |
| THERAPY | | | | | |
| Rystiggo | | | | | |
| ☐ Patients | s weighing less than | 50kg (110 lbs.) Rys | tiggo 420mg : | subQ weekly fo | or 6 weeks |
| ☐ Patients | s weighing 50kg to < | 100kg (220 lbs.) R | ystiggo 560m | g subQ weekly | for 6 weeks |
| ☐ Patients | s weighing ≥100kg (2 | 220 lbs.) Rystiggo 8 | 340mg subQ v | weekly for 6 we | eeks |
| | pe repeated based or ne | | | ≥63 days from sta | art of previous cycle |
| Other order | S: | | | | |
| Lab Orders: | F | Freque | ncy: □ Everv | infusion ☐ Otl | her: |
| | os to be drawn by: | | | | |
| | injection Ana-kit (adult): e per protocol EpiPen 0.3 | | | | |
| PROVIDER | INFORMATION | | | | |
| agent in dealing with r | medical and prescription insurance co | mpanies, and to select the preferr | ed site of care for the pat | ient. | n and specialty pharmacy designated Date: Dn: |
| | D LOCATION | e or care (If checked | , piease list site | or care): | |
| PREFERRE | LOCATION | | | | |
| City | State | o: | | | |



COMPREHENSIVE SUPPORT FOR RYSTIGGO THERAPY

| PATIENT INFORMATION: |
|--|
| Patient Name: DOB: |
| REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL |
| ☐ Include <u>signed</u> and <u>completed</u> order (MD/prescriber to complete page 1) |
| ☐ Include patient demographic information and insurance information |
| ☐ Include patient's current medication list |
| ☐ Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy |
| ☐ Has the patient had a documented contraindication/intolerance or failed trial of conventional therapy (i.e., pyridostigmine, immunosuppressants, corticosteroids, or acetylcholinesterase inhibitors)? ☐ Yes ☐ No If yes, which drug(s)? |
| ☐ Has the patient required 2 or more courses of plasmapheresis/plasma exchanges and/or intravenous immune globulin for at least 12 months without symptom control? ☐ Yes ☐ No |
| Myasthenia Gravis Activities of Daily Living (MG-ADL) Score: |
| Does patient have a history of abnormal neuromuscular transmission test demonstrated by single-fiber electromyography (SFEMG) or repetitive nerve stimulation? Yes No |
| \square Does the patient have a history of positive anticholinesterase test? \square Yes \square No |
| ☐ Include labs and/or test results to support diagnosis |
| AChR antibodies <u>or</u> MuSK antibodies (required) |
| ☐ If ordering a subsequent treatment cycle, and patient is new to Vital Care, please indicate the start date of the last completed cycle |
| Other medical necessity: |
| |

Vital Care will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (866) 790-3580 or call (945) 212-3707 for assistance